Niacin subsensitivity is associated with functional impairment in schizophrenia

Schizophrenia Research

Volumn 137, Issue 1-3, 2012, Pages 180-184

  Messamore, Erik ^a,b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Laser doppler flowmetry; Niacin; Psychiatric status rating scales; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; NICOTINIC ACID; NICOTINIC ACID METHYL ESTER;

ADULT; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DRUG SENSITIVITY; FEMALE; FUNCTIONAL DISEASE; GLOBAL ASSESSMENT OF FUNCTIONING SCORE; HUMAN; MALE; NIACIN SUBSENSITIVITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM;

ADMINISTRATION, CUTANEOUS; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUSHING; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; NIACIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SKIN; STATISTICS AS TOPIC;

EID: 84860836991     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.001     Document Type: Article

References (47)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, Washington, D.C. 4th ed.
2. Benyo Z., Gille A., Bennett C.L., Clausen B.E., Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharmacol. 2006, 70(6):1844-1849.
3. Berger, G., Yuen, H., McGorry, P., 2002. The topical niacin flush test in early psychosis [Abstract]. Schizophr. Res. 53 S38.
4. Bosveld-van Haandel L., Knegtering R., Kluiter H., van den Bosch R.J. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res. 2006, 143(2-3):303-306.
5. Cao Y., Murphy K.J., McIntyre T.M., Zimmerman G.A., Prescott S.M. Expression of fatty acid-CoA ligase 4 during development and in brain. FEBS Lett. 2000, 467(2-3):263-267.
6. Covault, J., Pettinati, H., Moak, D., Mueller T., Kranzler, H.R., 2004. Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. Am. J. Med. Genet. Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics. 127 (1) 42-47.
7. D'Agostino R.B. Tests for the normal distribution. Goodness-of-Fit Techniques 1986, 367-420. Marcel Dekker, New York. R.B. D'Agostino, M.A. Stepenes (Eds.).
8. Eklund B., Kaijser L., Nowak J., Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins. 1979, 17(6):821-830.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1997, American Psychiatric Press, Washington, D.C.
10. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 1994, 12(1):53-61.
11. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Prostaglandins Leukot. Essent. Fatty Acids. 1996, 55(1-2):9-15.
12. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 2000, 26(1):119-136.
13. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?. Biol. Psychiatry. 1997, 41:507-513.
14. Hudson C., Gotowiec A., Seeman M., Warsh J., Ross B.M. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia. Biol. Psychiatry. 1999, 46(3):401-405.
15. Joseph J.A., Kandasamy S.B., Hunt W.A., Dalton T.K., Stevens S. Radiation-induced increases in sensitivity of cataleptic behavior to haloperidol: possible involvement of prostaglandins. Pharmacol. Biochem. Behav. 1988, 29(2):335-341.
16. Katzman M., Cornacchi S., Coonerty-Femiano A., Hughes B., Vermani M., Struzik L., Ross B.M. Methyl nicotinate-induced vasodilation in generalized social phobia. Neuropsychopharmacology. 2003, 28:1846-1851.
17. Keshavan M.S., Nasrallah H.A., Tandon R. Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse. Schizophr. Res. 2011, 127(1-3):3-13.
18. Light, G.A., Braff, D.L., 2005. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 162 1741-1743.
19. Lin A., Hudson C.J. The niacin challenge test in schizophrenia: past, present and future. Prostaglandins Leukot. Essent. Fatty Acids. 1996, 55(1-2):17-19.
20. Liu, C.M., Chang, S.S., Liao, S.C., Hwang, T.J., Shieh, M.H., Liu, S.K., Chen, W.J., Hwu, H.G., 2007. Absent response to niacin skin patch is specific to schizophrenia and independent of smoking. Psychiatry Res. 152 181-187.
21. Maclean R., Ward P.E., Glen I., Roberts S.J., Ross B.M. On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003, 27(6):927-933.
22. Messamore E. Relationship between the niacin skin flush response and essential fatty acids in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 2003, 69(6):413-419.
23. Messamore E., Hoffman W.F., Janowsky A. The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study. Schizophr. Res. 2003, 62(3):251-258.
24. Messamore E., Hoffman W.F., Yao J.K. Niacin sensitivity and the arachidonic acid pathway in schizophrenia. Schizophr. Res. 2010, 122(1-3):248-256.
25. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 1992, 98(5):812-815.
26. Naidu P.S., Kulkarni S.K. Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002, 26(5):819-822.
27. Nielsen J.A., Sparber S.B. A comparative study of the effects of prostaglandins and d-amphetamine on the metabolism of 3H-dopamine continuously presented to rat brain in vivo. Pharmacol. Biochem. Behav. 1984, 21(4):583-589.
28. Nilsson B.M., Hultman C.M., Wiesel F.A. Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls. Prostaglandins Leukot. Essent. Fatty Acids. 2006, 74(5):339-346.
29. Nishino S., Mignot E., Benson K.L., Zarcone V.P. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 1998, 78(3):141-150.
30. Niwa K., Araki E., Morham S.G., Ross M.E., Iadecola C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J. Neurosci. 2000, 20(2):763-770.
31. Ono N., Saito R., Abiru T., Kamiya H., Furukawa T. Possible involvement of prostaglandins in cataleptic behavior in rats. Pharmacol. Biochem. Behav. 1986, 25(2):463-467.
32. Ono N., Abiru T., Sugiyama K., Kamiya H. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukot. Essent. Fatty Acids. 1992, 46(1):59-63.
33. Poddubiuk, Z.M., Kleinrok, Z., 1976. A comparison of the central actions of prostaglandins A1, E1, E2, F1alpha, and F2alpha in the rat. II. The effect of intraventricular prostaglandins on the action of some drugs and on the level and turnover of biogenic amines in the rat brain. Psychopharmacology (Berl). 50 (1) 95-102.
34. Puri B.K., Richardson A.J., Easton T. Association of niacin flush response with schizophrenia symptoms [Abstract]. Schizophr. Res. 2000, 41(1):251.
35. Puri B.K., Hirsch S.R., Easton T., Richardson A.J. A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2002, 26:49-52.
36. Puri B.K., Richardson A.J., Counsell S.J., Ward P.E., Bustos M.G., Hamilton G., Bhakoo K.K., Treasaden I.H. Negative correlation between cerebral inorganic phosphate and the volumetric niacin response in male patients with schizophrenia who have seriously and dangerously violently offended: a (31)P magnetic resonance spectroscopy study. Prostaglandins Leukot. Essent. Fatty Acids. 2007, 77(2):97-99.
37. Ross B.M., Hughes B., Turenne S., Seeman M., Warsh J.J. Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry. Eur. Neuropsychopharmacol. 2004, 14:191-197.
38. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry. 1991, 29(8):834-836.
39. Schwarz R.D., Uretsky N.J., Bianchine J.R. Prostaglandin inhibition of apomorphine-induced circling in mice. Pharmacol. Biochem. Behav. 1982, 17(6):1233-1237.
40. Smesny S., Berger G., Rosburg T., Riemann S., Riehemann S., McGorry P., Sauer H. Potential use of the topical niacin skin test in early psychosis - a combined approach using optical reflection spectroscopy and a descriptive rating scale. J. Psychiatr. Res. 2003, 37(3):237-247.
41. Smesny S., Rosburg T., Riemann S., Baur K., Rudolph N., Berger G., Sauer H. Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 2005, 72(6):393-402.
42. Smesny S., Klemm S., Stockebrand M., Grunwald S., Gerhard U.J., Rosburg T., Sauer H., Blanz B. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids. 2007, 77(2):79-85.
43. Smesny S., Rosburg T., Baur K., Rudolph N., Sauer H. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology. 2007, 32:2067-2073.
44. Tang Y., Zhou L., Gunnet J.W., Wines P.G., Cryan E.V., Demarest K.T. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem. Biophys. Res. Commun. 2006, 345(1):29-37.
45. Tavares H., Yacubian J., Talib L.L., Barbosa N.R., Gattaz W.F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 2003, 61:1-6.
46. Wanibuchi F., Usuda S. Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology (Berl). 1990, 102(3):339-342.
47. Ward P.E., Glen I. Oral and topical niacin flush testing in schizophrenia. Phospholipid Spectrum Disorders in Psychiatry 1999, 139-144. Marius Press, Carnforth, U.K. M. Peet, I. Glen, D.F. Horrobin (Eds.).